Business · 07/03/2025

FDA Denies Hearing Request for HETLIOZ Supplemental New Drug Application

The FDA has denied a request for a hearing regarding a proposal to refuse approval of a supplemental new drug application for HETLIOZ (tasimelteon) for treating insomnia, submitted by Vanda Pharmaceuticals, Inc. The decision is available on the FDA's website.